⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31378743 | 0.98 | — | — | |
| SCHEMBL29412943 | 0.81 | GNAO1 (0.34) | — | |
| SCHEMBL18997578 | 0.80 | — | — | |
| SCHEMBL23089568 | 0.77 | GBA1 (0.31) | — | |
| SCHEMBL3742325 | 0.77 | — | — | |
| SCHEMBL22169210 | 0.76 | — | — | |
| SCHEMBL25094066 | 0.75 | — | — | |
| SCHEMBL22017410 | 0.74 | GRM2 (0.33) | — | |
| SCHEMBL22016463 | 0.74 | HTR2A (0.30) | — | |
| SCHEMBL24875930 | 0.74 | GRM2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025016391-A1 | THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF | 南京再明医药有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-4417607-A1 | HETEROCYCLIC COMPOUND AS SOS1 INHIBITOR AND USES THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-08-21 | — | — | EP | disclosed |
| US-20240208972-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024108116-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117957226-A | Heterocyclic compounds as SOS1 inhibitors and uses thereof | 南京再明医药有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023041049-A1 | HETEROCYCLIC COMPOUND AS SOS1 INHIBITOR AND USES THEREOF | 江苏先声药业有限公司 | 2023-03-23 | — | — | WO | disclosed |
| EP-3328379-B1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3328379-B1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| US-10975066-B2 | Bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-04-13 | — | — | US | disclosed |
| WO-2020249664-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2019038384-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| US-20180222899-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3328379-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SPRL (BE) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017020010-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2523949-B1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2011086099-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |